SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730751.
  • 2
    Rolston KVI, Bodey GP. Infections in patients with cancer. In: Holland JF, Frei E, editors. Cancer Medicine, 6th ed. Ontario: BC Decker; 2003: 26332658.
  • 3
    Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med. 1993; 328: 13231332.
  • 4
    Rolston K. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999; 29: 515521.
  • 5
    Feld R, Paesmans M, Freifeld AG, et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis. 2002; 35: 14631468.
  • 6
    Talcott JA, Seigel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992; 10: 316322.
  • 7
    Klastersky J, Paesmans M, Rubenstein E, et al. The MASCC Risk Index: a multinational scoring system to predict low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 8: 30383051.
  • 8
    Klastersky J, Barette M, Aoun M, et al. Oral treatment and early hospital discharge for low-risk (LR) febrile neutropenic patients (MASCC score ≥ 21) [abstract 43 PPO]. Presented at: 6th International Symposium on Febrile Neutropenia; December 17–19, 2003; Brussels, Belgium.
  • 9
    Malik IA, Abbas Z, Karim M. Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet. 1992; 339: 10921096.
  • 10
    Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999; 341: 305311.
  • 11
    Kern WV, Cometta A, de Bock R, Langenaeken J, Paesman M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999; 341: 312318.
  • 12
    Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994; 12: 107114.
  • 13
    Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective controlled single centre study. Br J Cancer. 2003; 89: 4349.
  • 14
    Santolaya ME, Alvarez AM, Aviles CL, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004; 22: 37843789.
  • 15
    Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med. 1995; 98: 224231.
  • 16
    Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low risk neutropenic cancer patients. Cancer. 1993; 71: 36403646.
  • 17
    Rolston K, Rubenstein EB, Elting L, et al. Ambulatory management of febrile episodes in low-risk neutropenic patients [abstract]. Presented at: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 1995; San Francisco, CA.
  • 18
    Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of febrile neutropenia in low risk pediatric cancer patients. Cancer. 1999; 86: 126134.
  • 19
    Freifeld AG, Brown AE, Elting L, NCCN Fever and Neutropenia Panel Members. Fever and neutropenia NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2004; 2: 390432.
  • 20
    Rolston KVI, Frisbee-Hume S, LeBlanc B, Streeter H, Ho DH. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis. 2003; 47: 441449.
  • 21
    Rolston KFI, Vaziri I, Frisbee-Hume S, Streeter H, LeBlanc B. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients. Chemotherapy. 2004; 50: 214220.
  • 22
    Diekema DJ, Jones RN, Rolston KVI. Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers. Diagn Microbiol Infect Dis. 1999; 34: 3743.
  • 23
    National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7–A5. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
  • 24
    Escalante CP, Weiser MA, Manzullo E, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer. 2004; 12: 657662.
  • 25
    Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004; 54: 2937.
  • 26
    Rolston KVI, Kontoyiannis DP, Yadegarynia D, Raad I. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005; 51: 215218.
  • 27
    Kamana M, Escalante E, Mullen C, Frisbee-Hume S, Rolston KV. Bacterial infections in low-risk, febrile neutropenic patients: over a decade of experience at a comprehensive cancer center. Cancer. 2005; 104: 422426.
  • 28
    Chamilos G, Bamias A, Efstathiou E, et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer. 2005; 103: 26292635.